Cytek Biosciences, Inc. CTKB
5.65
(0.08)
(1.40%)
as of 25 Sep
- Market cap
- $744.8M
- P/E
- 0.0×
Follow CTKB
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(3.36%) | (18.05%) | (20.93%) | (23.04%) | |
| (2.60%) | (13.85%) | (15.89%) | (17.14%) | ||
ROIC |
(16.92%) | (31.26%) | (41.67%) | (46.36%) | |
Return on Tangible Assets |
(3.87%) | (20.03%) | (23.21%) | (25.63%) | |
Average Days of Receivables |
105.02 | 113.23 | 92.79 | 87.76 | |
Free Cash Flow per Share |
(0.04) | (0.07) | (0.10) | (0.09) | |
Free Cash Flow |
(5.73) | (8.62) | (12.61) | (11.97) | |
Capital Expenditures |
(3.81) | (3.94) | (5.31) | (5.93) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(0.30%) | (0.78%) | (1.24%) | (1.03%) | |
Accounts Receivable Turnover |
3.60 | 3.27 | 3.82 | 3.90 | |
Accounts Payable Turnover |
14.07 | 16.25 | 15.19 | 12.67 | |
Inventory Turnover |
1.86 | 2.10 | 2.07 | 1.90 | |
Average Days of Payables |
30.41 | 24.11 | 24.95 | 31.74 | |
Days of Inventory on Hand |
205.80 | 182.17 | 184.29 | 197.27 | |
Tax Rate |
(0.17) | 1.23 | 1.06 | 0.97 | |
Research and Development Expense of Revenue |
18.91% | 18.10% | 17.80% | 18.03% | |
Selling, General and Administrative Expense of Revenue |
50.71% | 53.79% | 55.39% | 56.80% | |
Share Based Compensation of Revenue |
13.24% | 12.20% | 11.17% | 10.34% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.15 | 0.07 | 0.10 | 0.07 | |
Depreciation/Fixed assets |
0.65 | 0.66 | 0.58 | 0.57 | |
Capex/Depreciation |
(0.33) | (0.33) | (0.45) | (0.50) | |
Revenue per Share |
1.54 | 1.58 | 1.59 | 1.60 | |
Operating CF per Share |
(0.01) | (0.04) | (0.06) | (0.05) | |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.05) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 | |
Net Profit Margin |
(6.51%) | (33.02%) | (36.25%) | (38.98%) |
Columns are period end dates